Gyre Therapeutics, Inc.GYRENASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank29
3Y CAGR-6.4%
5Y CAGR-23.7%
Year-over-Year Change
Research and development spending
3Y CAGR
-6.4%/yr
vs -6.1%/yr prior
5Y CAGR
-23.7%/yr
Recent acceleration
Acceleration
-0.3pp
Decelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $13.70M | +13.9% |
| 2024 | $12.02M | -12.7% |
| 2023 | $13.78M | -17.4% |
| 2022 | $16.69M | -74.2% |
| 2021 | $64.57M | +21.9% |
| 2020 | $52.98M | +20.8% |
| 2019 | $43.86M | +104.2% |
| 2018 | $21.47M | +67.2% |
| 2017 | $12.85M | +11.2% |
| 2016 | $11.55M | - |